Monic MD - Marker Therapeutics Chief Officer
| MRKR Stock | USD 3.26 0.07 2.10% |
Executive
Monic MD is Chief Officer of Marker Therapeutics
| Address | 9350 Kirby Drive, Houston, TX, United States, 77054 |
| Phone | 713 400 6400 |
| Web | https://markertherapeutics.com |
Marker Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4087) % which means that it has lost $0.4087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7174) %, meaning that it created substantial loss on money invested by shareholders. Marker Therapeutics' management efficiency ratios could be used to measure how well Marker Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/27/2024, Return On Tangible Assets is likely to drop to -0.86. In addition to that, Return On Capital Employed is likely to grow to -0.99. At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 11/27/2024, Net Tangible Assets is likely to grow to about 53.1 M, while Non Current Assets Total are likely to drop 0.00.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Robert JD | Pmv Pharmaceuticals | 62 | |
| Caroline MD | Ikena Oncology | 52 | |
| FCA BEC | Bionomics Ltd ADR | 72 | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Julie Kerner | Bionomics Ltd ADR | N/A | |
| Stephen JD | Aadi Bioscience | 48 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| John Moore | Edgewise Therapeutics | 60 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| John MBA | Keros Therapeutics | N/A | |
| Leesa Gentry | RenovoRx | 54 | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Alfred Dadson | Agenus Inc | N/A | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Norah Conway | Alector | N/A | |
Management Performance
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.41 |
Marker Therapeutics Leadership Team
Elected by the shareholders, the Marker Therapeutics' board of directors comprises two types of representatives: Marker Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Marker. The board's role is to monitor Marker Therapeutics' management team and ensure that shareholders' interests are well served. Marker Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Marker Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gerald Garrett, Senior Operations | ||
| Juan MD, COO, CoFounder | ||
| Peter MBA, CEO Pres | ||
| Nadia Agopyan, Senior Affairs | ||
| MariaBernadette Madel, Director Communications | ||
| Monic MD, Chief Officer | ||
| Michael Loiacono, Treasurer Secretary | ||
| Mary Newman, Head Affairs | ||
| Robert Sr, Director Virology | ||
| Edmund Cheung, Vice Resources | ||
| Elizabeth Donnelly, Director Administration | ||
| Patricia Allison, Head Operations | ||
| Mythili MD, Chief Officer |
Marker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Marker Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.41 | ||||
| Profit Margin | (2.78) % | ||||
| Operating Margin | (1.97) % | ||||
| Current Valuation | 11.59 M | ||||
| Shares Outstanding | 8.92 M | ||||
| Shares Owned By Insiders | 12.19 % | ||||
| Shares Owned By Institutions | 22.44 % | ||||
| Number Of Shares Shorted | 70 K | ||||
| Price To Earning | (9.39) X |
Pair Trading with Marker Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Marker Stock
| 0.5 | MNOV | MediciNova | PairCorr |
| 0.45 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.39 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.35 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.
The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.